© 2021 MJH Life Sciences and Pharmacy Times. All rights reserved.
© 2021 MJH Life Sciences™ and Pharmacy Times. All rights reserved.
April 02, 2021
While the prevalence of COVID-19 in patients with COPD is relatively low, those who are infected with the virus experience more severe symptoms than those without COPD.
December 04, 2020
According to the survey results, 56% of patients with chronic obstructive pulmonary disease reported that COVID-19 has made it difficult for them to receive treatment
November 27, 2020
In the midst of the COVID-19 pandemic, it is important that individuals who are at higher risk for poor outcomes from infection with vaccine-preventable diseases remain up-to-date with their immunizations.
November 18, 2020
Pharmacists should familiarize themselves with these therapies to help patients lessen the risk of emergency department visits and hospitalizations.
November 16, 2020
In the study, more patients with allergies had chronic obstructive pulmonary disease (COPD), which is a known risk factor for severe disease with COVID-19.
October 26, 2020
They can help patients improve inhalation technique, ensuring better medication adherence.
September 21, 2020
Digital health tools were a major theme during the first-ever NASP Challenge, comprising 4 of the 5 finalists.
September 14, 2020
The triple combination therapy is the first single inhaler triple therapy approved for both asthma and COPD and is the only single inhaler triple therapy available as a once-daily inhalation.
August 11, 2020
Chronic obstructive pulmonary disease may remain undetected due to individuals thinking that the symptoms are a normal sign of aging.
July 24, 2020
Budesonide/glycopyrrolate/formoterol fumarate (Breztri Aerosphere, AstraZeneca) has been approved by the FDA for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD), according to a press release.